Showing 3581-3590 of 20433 results for "".
- Immunotherapy Effective on Young Children’s Peanut Allergieshttps://reachmd.com/news/immunotherapy-effective-on-young-childrens-peanut-allergies/2456816/(Photo credit: Getty Images) DALLAS – Nov. 07, 2023 – Low doses of an immunotherapy taken under the tongue safely achieved desensitization to peanut allergies in children ages 1 to 4 years, according to results of a clinical trial conducted b
- Advancements in Food Allergy Research Promise Improved Diagnosis and Treatment Optionshttps://reachmd.com/news/advancements-in-food-allergy-research-promise-improved-diagnosis-and-treatment-options/2456815/A comprehensive review of food allergy (FA)-related studies published between 2021 and 2023 is currently in press with the Journal of Allergy and Clinical Immunology</
- National Cardiogenic Shock Initiative Publishes Final Resultshttps://reachmd.com/news/national-cardiogenic-shock-initiative-publishes-final-results/2456789/December 18, 2023—Henry Ford Health in Detroit, Michigan, recently announced the publication of final results from the National Cardiogenic Shock Initiative (NCSI), which was led by a cardiology research team based at Henry Ford Hospital. The press releas
- Clinician Drug-Drug Interaction Choices Enhance Patient Safetyhttps://reachmd.com/news/clinician-drug-drug-interaction-choices-enhance-patient-safety/2456793/INDIANAPOLIS — Drug-drug interactions causing adverse effects are common and can cause significant patient harm and even death. A new study is one of the first to examine how clinicians become aware of and process information about potential interactions and subsequently make their
- Novel Compound Protects Against Infection by Virus That Causes COVID-19, Preliminary Studies Showhttps://reachmd.com/news/novel-compound-protects-against-infection-by-virus-that-causes-covid-19-preliminary-studies-show/2456778/Design and screening of stapled lipopeptide inhibitors of SARS-CoV-2. a Schematic of the six-helix bundle (6-HB) fusion mechanism of SARS-CoV-2 and the mechanism by which a stapled
- Melanoma Rates Among Non-Hispanic American Indian/Alaska Natives Vary by Age, Regionhttps://reachmd.com/news/melanoma-rates-among-non-hispanic-american-indianalaska-natives-vary-by-age-region/2456775/A new study in JAMA Dermatology shed light on trends and incidence rates of invasive cutaneous melanoma in non-Hispanic American Indian/Alaska Native individuals. The cross-sectional observational study, focusing on a period from 1999
- Size & Shape of Inhaled Asbestos Nanofibers May Be Exclusively Responsible for Pulmonary Fibrosishttps://reachmd.com/news/size-shape-of-inhaled-asbestos-nanofibers-may-be-exclusively-responsible-for-pulmonary-fibrosis/2456786/Pseudo-colored scanning electron microscopy image: phagocytosis by a macrophage (red) of glass nanofibers (blue) after 12 h of frustrated phagocytosis; scale bar, 5 μm. Credit: Nature Nan
- IDOR Participated in a Study Evaluating Selpercatinib for the Treatment of Non-Small Cell Lung Cancerhttps://reachmd.com/news/idor-participated-in-a-study-evaluating-selpercatinib-for-the-treatment-of-non-small-cell-lung-cancer/2456783/D’Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pemb
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://reachmd.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled
- RSV Vaccines Would Greatly Reduce Illness If Implemented Like Flu Shotshttps://reachmd.com/news/rsv-vaccines-would-greatly-reduce-illness-if-implemented-like-flu-shots/2456750/Respiratory syncytial virus (RSV) vaccines recently approved for people 60 and older would dramatically reduce the disease’s significant burden of illness and death in the United States if they were widely adopted like annual influenza vaccines, a new study has found. A high leve